Efficacy and safety of tolterodine in subjects with symptoms of overactive bladder: An open label, noncomparative, prospective, multicentric study

Indian Journal of Urology

Volumn 19, Issue 1, 2002, Pages 73-78

  Kumar, Anant ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antimuscarinic; Detrusor; Hyperreflexia; Overactive bladder; Tolterodine

Indexed keywords

AMLODIPINE; ATENOLOL; DOXAZOSIN; LIVER ENZYME; NIFEDIPINE; OXYBUTYNIN; PARACETAMOL; TOLTERODINE;

ADULT; AGED; ANXIETY; ARTICLE; AUTONOMIC DYSFUNCTION; BILIARY TRACT DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSULTATION; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING DISORDER; HEMATURIA; HUMAN; HYPOKINESIA; INDIA; INDIAN; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL DISEASE; METABOLIC DISORDER; MICTURITION; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NUTRITIONAL DISORDER; OPEN STUDY; OVERACTIVE BLADDER; PARESTHESIA; PATIENT ATTITUDE; PERCEPTION; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; URINE VOLUME; VESTIBULAR DISORDER; XEROSTOMIA;

EID: 0036766560     PISSN: 09701591     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bent AE. Etiology and management of detrusor instability and mixed incontinence. Obstet Gyneco Clin North Am 1989; 16: 853-868.
2. Anderson KE. Current concepts in the treatment of disorders of micturition. Drugs 1988; 35: 477-494.
3. Yarker YE, Goa KL, Fitton A. Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability. Drugs and Aging 1995; 6: 243-262.
4. Abrams P, Freeman RN, Andersrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with overactive bladder. Br J Urology 1998; 81: 801-810.
5. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997; 50 (suppl): 90-96.
6. Nilvebrant L, Anderson KE, Gillberg PG et al. Tolterodine - A new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207.
7. Nilvebrant L, Hallen B, Larsson G. Tolterodine - A new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data. Life Sci 1997; 60: 1129-36.
8. Naerger H, Fry CH, Nilvebrant L. Effect of tolterodine on electrically induced bladder contractions of isolated human detrusor muscle from stable and unstable bladders. Neurourol Urodyn 1995; 14: 524-526.
9. Nilvebrant L, Glas G, Johnsson A, Sparf B. The in vitro pharmacological profile of tolterodine - A new drug for the treatment of urinary urge incontinence. Neurourol Urodyn 1994; 13: 433-435.
10. Nilvebrant L, Stahl M, Andersson KE. Interaction of tolterodine with cholinergic muscarinic receptors in human detrusor. Neurourol Urodyn 1994; 14: 423-524.
11. Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 81: 169-172.
12. Jeppson L et al. A phase II randomized, double-blind, placebo-controlled, parallel-group, dose ranging, multicentric study of safety and efficacy of tolterodine in patients with detrusor instability. A multicentric study of Sweden and UK. CTN 92-OATA -002. Pharmacia document: 9400697; 1995.
13. Kohlerstrand E et al. A phase II randomized, double-blind, placebo-controlled, parallel-group, dose ranging, multicentric study of the safety and efficacy of tolterodine in patients with detrusor hyperreflexia. A multicentric study in the Netherlands, France, Germany and Austria. CTN 93-OATA-005. Pharmacia document: 9400712, 1995.
14. Kohlerstrand E et al. A phase II randomized, double-blind, placebo-controlled, parallel-group, dose ranging, multicentric study of the safety and efficacy of tolterodine in patients with detrusor instability. A multicentric study in France, Norway and Denmark. CTN 93-OATA-006. Pharmacia document: 9400711, 1995.